SINUS WASH Pilot Study in Adults Testing Positive for COVID-19

Coronavirus Infection Clinical Trial

Official title:

Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04393792
• Other study ID #: SPON-AK-0420
• Secondary ID: 2020-001721-31
• Status: Recruiting
• Phase: Phase 1
• Start date: May 5, 2020
• Est. completion date: March 2022

Study information

• Verified date: September 2021
• Source: Hampshire Hospitals NHS Foundation Trust
• Contact: Afroze Khan, MBBS MRCS
• Phone: +447885903693
• Email: Afroze.Khan[@]nhs.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.

Description:

COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that reaches other parts of the body. This also could mean that there is less virus available to pass on to others. We want to see if the use of nasal rinsing and mouth washes will reduce the spread of infection within your household by reducing and removing the virus from your mouth and nose. Once the participants have been recruited they will be randomly allocated to one of two groups. Each arm will have the same number of participants. The two arms will be : 1. nose rinse and mouthwash with Isotonic saline alone. This will be the control arm. 2. nose rinse and mouthwash with Povidone-Iodine taken 3 times a days for three days. Before treatment begins, each participant will have one pre-treatment swab of the back of the nose and the back of the throat taken. Once allocated each participant will be asked to have 4 further swabs of the mouth and nose taken on days 2,4,7 & 14. Participants will be patients and healthcare staff who have tested positive for COVID-19. Healthcare staff who are self isolating will also asked their co-residents/family members at home to take the treatment and provide swabs in the same manner. Participants who are patients and are admitted to hospital will be well enough to perform the nasal rinses and mouth washes as treatments and provide the same swabs. All participants will be provided with informational videos on how to do the treatments and how to take the swabs. Participants who are not healthcare staff will have swabs taken as part of the local drive through testing service. All participants will be asked to download a free smartphone app (Umotif) to upload information about daily symptoms and whether they have provided swabs on the required days. The swabs will be tested for the amount of virus in the labs at Hampshire Hospitals NHS Foundation Trust and analysed to determine if the treatment arm of Povidone-Iodine is reducing the amount of virus compared to the isotonic saline arm. All results will be anonymised prior to analysis. The study team will know the participants' study-specific data; no personal data about participants will be used without their explicit consent and only for the purposes of protocol adherence and data to answer the study question. Once the last swab has been taken and delivered to the laboratory, the trial will have ended for that participant. Results of the swabs will be part of the study data and collated in readiness for analysis by the study statistician. The results will be made available for peer-reviewed publication and presentation at conferences.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthcare worker OR patient on a general ward who has had a positive COVID-19 test OR a person who is co-residing with an affected staff member or patient who is now at home in self-isolation.
• capable of giving informed consent
• able to self-administer the sinus rinses and mouth washes
• able to have healthcare professional-led swabs OR self-administer the oral and nasopharyngeal swabs
• aged 18 years and over.

Exclusion Criteria:

• not capable of giving informed consent
• unable to self-administer the sinus rinses and mouth washes
• unable to have healthcare professional-led swabs OR self-administer the oral, nasal and/OR nasopharyngeal swabs
• unable to send swabs to the study team via the approved methods described in participant information leaflet and protocol
• under 18 years of age.
• known hypersensitivity to Iodine
• at risk of aspiration due to an unsafe swallow
• hyperthyroidism or other manifest thyroid diseases
• herpetiform dermatitis (Duhring's disease)
• planned or undergoing radioiodine treatment
• actively Breastfeeding
• pregnant

Related Conditions & MeSH terms

• Coronavirus Infection
• Coronavirus Infections
• COVID-19

Intervention

Drug:
• Povidone-Iodine
0.23% three times daily (tds) for 3 days
• Normal saline
0.9% three times daily (tds) for 3 days

Locations

Country	Name	City	State
United Kingdom	Hampshire Hospitals NHS Foundation Trust	Basingstoke	Hampshire

Sponsors (1)

Lead Sponsor	Collaborator
Hampshire Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in viral load in the oral and nasopharyngeal cavity	viral load as measured by real time polymerase chain reaction (PCR)	Day 0, 2, 3, 7, 14
Secondary	Symptom severity in primary participants and co-residents	Visual analogue score 1-5 per symptom via a smartphone app	Days 0 to 14